Endologix, Inc. (Nasdaq:ELGX), developer and manufacturer of the
Powerlink(R) System endoluminal stent graft (ELG) for the minimally
invasive treatment of abdominal aortic aneurysms (AAA), today
announced financial results for the three months and six months
ended June 30, 2006. "Our domestic product sales increased by more
than three-fold year-over-year and by 31% on a sequential quarter
basis," said Endologix President and Chief Executive Officer Paul
McCormick. "We believe our sales growth reflects positively on the
steps we are taking to accelerate our domestic launch, including
the hiring of sales representatives with prior AAA experience, and
indicates an increasing market acceptance of the Powerlink System.
We now have 33 sales representatives on board and three more
committed to start in August. We are well on our way toward
increasing our sales rep headcount to between 40 and 50 by the end
of this year. "Additionally during the quarter we initiated a
controlled launch of our next-generation Visiflex(TM) Delivery
System for use with the Powerlink System. The Visiflex catheter has
improved flexibility with attributes to enhance catheter visibility
and facilitate smoother withdrawal in difficult anatomies. Based on
the highly positive feedback from physicians performing procedures
with the Visiflex catheter, and our anticipated capacity to build
the appropriate inventory, we plan to complete a full transition to
the Visiflex Delivery System by the end of this year," added Mr.
McCormick. "We are also pleased to report that we have completed
the final phase of our plan to resolve issues with our catheter tip
that prompted our voluntary, limited catheter recall announced last
December. "With the completion of our financing in June, we believe
we are sufficiently capitalized to execute on our aggressive sales
plan and expect that our current cash balances will fund our
operations through cash flow break even. To support future growth,
we will look to leverage our Powerlink technology platform and our
direct sales organization to address additional, large market
applications," said Mr. McCormick. Second Quarter Financial Results
Product revenue for the second quarter of 2006 was $3.4 million, up
131% from $1.5 million in the second quarter of 2005 and up 29%
from $2.7 million in the first quarter of 2006. Domestic product
revenue was $2.8 million, compared with $900,000 in the 2005 second
quarter and $2.1 million in the 2006 first quarter. International
product revenue of $666,000 for the second quarter of 2006 compares
with $595,000 during the comparable quarter last year and $559,000
in the first quarter of 2006. The Company reported that domestic
product revenue for all periods predominantly represents product
usage. As consignment of product is customary in this market
segment, the Company believes that domestic product revenue will
approximate product usage for the foreseeable future. Gross profit
of $1.7 million was 49% of total revenue in the second quarter of
2006. This compares with $1.6 million and 59%, respectively, in the
first quarter of 2006. Margin in the 2006 second quarter included
the effect of a charge of $326,000 for a reserve to complete the
final phase of the Company's limited, voluntary catheter recall
announced in December 2005. The combined effect of this reserve
together with the effect of stock option expense in the second
quarter represents 10.2 margin percentage points. Total operating
expenses were $6.3 million in the second quarter of 2006, compared
with $4.0 million in the second quarter of 2005. The 2006 period
included $357,000 as a result of adopting SFAS No. 123(R),
Accounting for Stock-Based Compensation, on January 1, 2006. The
remaining increase primarily reflects the ongoing build out and
training of the domestic sales force. Marketing and sales expenses
increased to $3.2 million in the second quarter of 2006 from $1.7
million in the comparable quarter last year. The increase in
research, development and clinical expenses for the quarter ended
June 30, 2006 reflects the two new clinical trials now underway for
large diameter neck size products. General and administrative
expense increases include sales force recruitment fees and
contracted professional services. Endologix reported a net loss for
the second quarter of 2006 of $4.4 million, or $0.11 per share,
which compares with a net loss of $2.9 million, or $0.09 per share,
for the second quarter of 2005. The net loss for the second quarter
of 2006 included $388,000, or $0.01 per share, for stock-based
compensation expense. Year-to-Date Financial Results For the six
months ended June 30, 2006, product revenue was $6.1 million,
compared with $2.8 million for the six months ended June 30, 2005.
Gross profit of $3.3 million was 53% of total revenue for the six
months ended June 30, 2006. This compares with $1.7 million and
59%, respectively, in the first six months of 2005. The decrease in
margin percentage was due to the $326,000 inventory reserve charge
and costs associated with SFAS No. 123(R), Accounting for
Stock-Based Compensation. Total operating expenses for the first
six months of 2006 were $12.2 million, versus $8.2 million in
comparable period in 2005. The increase in operating expenses was
due primarily to the development of the Company's direct sales
force and the adoption of SFAS No. 123(R). Endologix reported a net
loss for the six months ended June 30, 2006 of $8.5 million, or
$0.23 per share, compared with a net loss of $6.2 million, or $0.19
per share, for the six months ended June 30, 2005. The net loss for
the first six months of 2006 included $736,000, or $0.02 per share,
for stock-based compensation expense. Total cash and marketable
securities as of June 30, 2006 was $28.6 million and included net
proceeds from the Company's direct equity financing completed in
June 2006. This compares with total cash and marketable securities
as of December 31, 2005 of $17.7 million. Conference Call
Information Endologix management will host a conference call to
discuss these topics today beginning at 5:00 p.m. Eastern time
(2:00 p.m. Pacific time). To participate via telephone please call
(888) 463-4487 from the U.S. or (706) 634-5615 from outside the
U.S. A telephone replay will be available for two days following
the completion of the call by dialing (800) 642-1687 from the U.S.
or (706) 645-9291 from outside the U.S., and entering reservation
number 2795893. The conference call will be broadcast live over the
Internet at www.endologix.com and will be available for 14 days.
About Endologix Endologix, Inc. develops and manufactures minimally
invasive treatments for vascular diseases. Endologix Powerlink
System is an endoluminal stent graft (ELG) for treating abdominal
aortic aneurysms (AAA). AAA is a weakening of the wall of the
aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
75%, making it the thirteenth leading cause of death in the U.S. In
October 2004, Endologix received approval to market the Powerlink
System in the U.S. Additional information can be found on
Endologix's Web site at www.endologix.com. Except for historical
information contained herein, this news release contains
forward-looking statements, the accuracy of which are necessarily
subject to risks and uncertainties, all of which are difficult or
impossible to predict accurately and many of which are beyond the
control of Endologix. Many factors may cause actual results to
differ materially from anticipated results including the success of
sales efforts for the Powerlink System, product research and
development efforts, and other economic, business, competitive and
regulatory factors. The Company undertakes no obligation to update
its forward looking statements. Please refer to the Company's
Annual Report on Form 10-K for the year ended December 31, 2005,
and the Company's other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied. -0- *T ENDOLOGIX, INC. CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per
share amounts) (Unaudited) Three Months Ended Six Months Ended June
30, June 30, 2006 2005 2006 2005 --------- -------- --------
-------- Revenue: Domestic Product Revenue $2,780 $900 $4,894
$1,521 Non-US Product Revenue 666 595 1,227 1,328 ---------
-------- -------- -------- Total Product Revenue 3,446 1,495 6,121
2,849 License Revenue 49 67 107 127 --------- -------- --------
-------- Total revenue 3,495 1,562 6,228 2,976 Cost of product
revenue 1,798 584 2,917 1,227 --------- -------- -------- --------
Gross profit 1,697 978 3,311 1,749 --------- -------- --------
-------- Operating expenses: Research, development and clinical
1,830 1,473 3,517 2,832 Marketing and sales 3,152 1,717 5,750 3,095
General and administrative 1,325 789 2,926 2,228 --------- --------
-------- -------- Total operating expenses 6,307 3,979 12,193 8,155
--------- -------- -------- -------- Loss from operations (4,610)
(3,001) (8,882) (6,406) --------- -------- -------- -------- Other
income: Interest income 208 103 367 212 Other income (expense) 14
(5) 15 (5) --------- -------- -------- -------- Total other income
222 98 382 207 --------- -------- -------- -------- Net loss
($4,388) ($2,903) ($8,500) ($6,199) ========= ======== ========
======== Basic and diluted net loss per share ($0.11) ($0.09)
($0.23) ($0.19) ========= ======== ======== ======== Shares used in
computing basic and diluted net loss per share 38,203 31,911 37,345
31,903 ========= ======== ======== ======== ENDOLOGIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands except par
values) (Unaudited) June December 30, 31, 2006 2005 ---------
-------- ASSETS Current assets: Cash and cash equivalents $22,094
$8,191 Restricted cash equivalents 500 500 Marketable securities
available-for-sale 4,490 8,959 Accounts receivable, net 2,160 1,248
Other receivables 219 175 Inventories 6,905 7,372 Other current
assets 331 576 --------- -------- Total current assets 36,699
27,021 Property and equipment, net 4,694 4,490 Marketable
securities available-for-sale 1,498 -- Goodwill 4,631 4,631
Intangibles, net 11,021 11,724 Other assets 78 78 ---------
-------- Total Assets $58,621 $47,944 ========= ========
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts
payable and accrued expenses $2,995 $4,501 --------- --------
Current liabilities 2,995 4,501 Long term liabilities 1,204 1,236
--------- -------- Total liabilities 4,199 5,737 --------- --------
Stockholders' equity: Convertible preferred stock, $.001 par value;
5,000 shares authorized, no shares issued and outstanding Common
stock, $.001 par value; 50,000 shares authorized, 43,094 and 36,679
shares issued and outstanding at June 30, 2006 and December 31,
2005, respectively 43 37 Additional paid-in capital 162,586 141,903
Accumulated deficit (107,620) (99,120) Treasury stock, at cost, 495
shares at June 30, 2006 and December 31, 2005 (661) (661)
Accumulated other comprehensive income 74 48 --------- --------
Total stockholders' equity 54,422 42,207 --------- -------- Total
Liabilities and Stockholders' Equity $58,621 $47,944 =========
======== *T
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024